BIOLOGICAL · Unmapped registry intervention
ALECSAT
Find medicine records ·
Find other trials using this name
Clinical trial
Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy
NCT01422850
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedSafety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Hormone-refractory Prostate Cancerunresolved
Interventions
ALECSATBIOLOGICAL
Sponsors & collaborators
CytoVac A/Slead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01422850 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.